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Abstract: Background/Objective: Protein-based drugs are increasingly used to treat a 
variety of conditions including cancer and cardio-vascular disease. Due to the immune 
system’s innate ability to degrade the foreign particles quickly, protein-based treatments 
are generally short-lived. To address this limitation, the objective of the study was to: 1) 
develop protein-loaded liposomes; 2) characterize size, stability, encapsulation efficiency 
and rate of protein release; and 3) determine intracellular uptake and distribution; and 
4) protein structural changes. 
Method: Liposomes were loaded with a fluorescent-albumin using freeze-thaw (F/T) 
methodology. Albumin encapsulation and release were quantified by fluorescence 
spectroscopic techniques. Flow cytometry was used to determine liposome uptake by 
macrophages. Epifluorescence microscopy was used to determine cellular distribution of 
liposomes. Stability was determined using dynamic light scattering by measuring 
liposome size over one month period. Protein structure was determined using circular 
dichroism (CD). 
Result: Encapsulation of albumin in liposome was ~90% and was dependent on F/T 
rates, with fifteen cycles yielding the highest encapsulation efficacy (p < 0.05). Albumin-
loaded liposomes demonstrated consistent size (<300nm). Release of encapsulated 
albumin in physiological buffer at 25°C was ~60% in 72 h. Fluorescence imaging 
suggested an endosomal route of cellular entry for the FITC-albumin liposome with 
maximum uptake rates in immune cells (30% at 2hour incubation). CD suggested 
protein structure is minimally impacted by freeze-thaw methodology. 
Conclusion: Using F/T as a loading method, we were able to successfully achieve a 
protein-loaded liposome that was under 300nm, had encapsulation of ~90%. 
Synthesized liposomes demonstrated a burst release of encapsulate protein (60%)  at 72 
hours. Cellular trafficking confirmed endosomal uptake, and minimal protein damage 
was noticed in CD.  
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CHAPTER I 
 
 
INTRODUCTION 
Limitations of Conventional Therapy 
Medicine has come a long way since the time of Galen in the 1500’s. The production 
of antibiotics, cancer drugs, cardiovascular drugs, and now genomic treatments are a 
testament to its advancement. These discoveries are allowing treatment of a wide variety of 
ailments including  infectious diseases that once was the number one killer due to lack of 
aseptic technique (Miller, et al., 2005). Similarly, cancer survival rates have steadily inclined 
due to the development of new drugs and treatments.  
 
Despite significant advances in human medicine, current treatment approaches rely 
on systemic delivery with limited organ specificity, and therefore result in adverse side 
effects in normal tissues and insufficient drug delivery to the target tissue. Drugs can also be 
filtered from the blood prior to its intended effect. At low doses of drug compounds, the 
human liver and kidneys can metabolize and clear molecules that are less than 60KDa 
(Hagenbuch, 2010; Shitara, et al., 2006).  However, at higher doses, the clearance of drug is 
influenced at many levels. For example, absorption of drug molecules from gastrointestinal 
tract is pH dependent and can be retained differently based on the chemical composition of 
the drug (Hagenbuch, 2010). The administered drugs can be metabolized in liver, and may 
create products that are toxic to healthy tissues.  Similarly, renal filtration and removal of 
drugs are helpful if the substance is toxic and needs to be removed rapidly; however, if the 
drug is removed before it reaches the target organ, or is trapped within a certain organ due 
to its chemical make-up (hydrophilic drugs vs. hydrophobic drugs), the desired clinical 
outcomes are not achieved. Thus, new approaches that maintain the efficacy while reducing 
the toxicity of drugs are needed . 
Nanomedicine 
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 Nanotechnology is a multidisciplinary scientific field focused on materials whose 
physical and chemical properties can be controlled at the nanoscale range (1–1000 nm) by 
incorporating chemistry, engineering, and manufacturing principles (Kim et al., 2010). The 
convergence of nanotechnology and medicine, suitably called nanomedicine, can potentially 
advance the fight against a range of diseases (Sanhai et al., 2008). Nanomedicine can sustain 
drug release, increase solubility and bioavailability, decrease aggregation and improve 
efficacy (Ranjan et al 2011). Additionally, the use of nanoparticles may decrease toxicity of 
drugs (Byrne, et al., 2008) and increase the ability to target the drug to the correct tissue 
(Jain, 2006; Coti, et al., 2009). Drugs, proteins, or genes have been successfully loaded into 
differing nanoparticles, and many have made it to clinical trials. For clinical translation, 
Food and Drug Administration recommends that nanoparticle size be less than 300nm 
(Food and Drug Administration, et al., 2002).  To achieve this, various nanoparticles are 
created from a variety of materials. For example, some nanoparticles are polymer based and 
have a cage-like structure while others are created from heavy metals such as gold. In 
contrast, liposome nanoparticles mimic a cell with a lipid bilayer and aqueous core. 
 
Liposomal Nanomedicine 
 Liposomes were first described in 1961 by Alec Bangham (Deamer, 2010). 
Structurally, liposomes are composed of a lipid bilayer with  hydrophobic tails in the center 
and hydrophilic heads on the outside. The aqueous core allows for loading of different 
materials, and the outside can have different peptides or proteins attached for cellular 
targeting. Liposomes can be multilamellar (multiple lipid bilayers stacked) or unilamellar 
(single lipid bilayer), and may have different size and charge chemistry. In general, larger 
liposomes are relatively quickly taken up by the reticoluendothelial system (Machy & 
Lesserman, 1983). This can be addressed by decorating liposome surface with polyethylene 
glycol (PEG)-based polymers. PEGylation helps to increase the half-life of liposomes in a 
biological system (Maruyama, et al., 1992), prevents uptake by the immune system (Ishida, 
et al., 2002), and consequently reduces its clearance from the circulation 
 As a drug delivery system (DDS), liposomes can encapsulate both hydrophilic and 
hydrophobic molecules, and thus are widely translatable against a variety of clinical 
conditions (Gregoriadis, 1985). Clinically, liposomes achieve higher volume of distribution 
and solubilization of drug molecules in blood and thereby can decrease the unwanted side 
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effects. For example, liposomes can decrease the toxicity of drugs such as gentamicin, which 
is used for bacterial infections (Frierer, et al., 1990), or doxycycline which is also an 
antibiotic and doxorubicin for cancer treatments (Green & Rose, 2006).  
Liposome mediated site directed drug delivery can be achieved by various methods 
(Chan & Yeh, 2012). For example, a pH sensitive liposome upon reaching the target tissue 
will release its content based on the pH difference (e.g. cell endosomes) (Cho, et al., 2008). 
Alternatively, heat-sensitive liposomes keep the drug in its aqueous core at body 
temperature, but when a particular spot of the body is heated to 42⁰C, the liposomes release 
the cargo. Other methods of targeting include using cell receptor specific peptides or 
antibodies (Wang & Thanou, 2010). Finally, the highly pegylated stealth liposome can 
circulate for long time (-48-72 h) with very slow systemic release, and eventually accumulate 
in tumors by enhanced permeation to provide targeted drug release (Kim, et al., 1987). Next 
we discuss the application of liposomes for delivery of protein-based therapeutics. 
 
Protein-Based Treatments 
 In the last few decades, protein or DNA-based drugs are being increasingly applied in 
medicine. Examples include the use of thrombokinase for stroke or burtrylcholinesterase 
against nerve agents. Acetylcholinesterase is an enzyme that breaks down acetylcholine from 
muscle junctions, but organophosphorus insecticides and nerve agents can inhibit this 
enzyme. This prevents the breakdown of acetylcholine and leads to a build-up of 
acetylcholine which leads to excessive salivating, seizures, and respiratory failure (Zimmer, 
et al., 1998). Drugs such as atropine can reverse these effects. Protein therapeutics have a 
fast clearance and require administration at the moment of exposure.  Additionally,  the in 
vivo usage of protein is limited by its purity and amount (Kimichi-Sarfaty, et al., 2013). 
Proteins have to be purified from their source before use. As such, it can be challenging to 
procure a large amount of pure protein from a consistent source. To address this, a major 
focus in this area of work is on the discovery of recombinant proteins that may last up to a 
week in the human body (Cohen, et al., 2006) compared to native protein. Alternatively, 
protein-based therapeutics can be combined with nanocarriers (e.g. liposomes) to reduce 
frequency and dosage of treatment. For example, in Putney and coworkers  (1998) study, 
they observed the stability of protein-polymers had extended periods in vivo after injection.  
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Liposomes and Protein-Based treatments 
 The use of liposomes for protein-based therapy has been extensively investigated and 
reported previously. One example of liposome use could be in the case of prions, liposomes 
were combined with a PrP-27-30 protein. By doing this Gabizon contended that this protein 
was necessary for infectivity of the prion virus (Gabizon, et al., 1988). However, liposomes 
can also be used to encapsulate other proteins for uses in treatment. These methods of 
encapsulation can increase the circulation time by preventing the immune system access and 
increase the targetability of the protein. For example, thrombokinase, which can cause 
hemorrhage in its native state, could theoretically be encapsulated to prevent unwanted 
damage to blood vessels and reach its target destination. Similarly, proteins incorporated 
into the lipid bilayer of liposomes have shown to enhance vaccination response (Bucher, et 
al., 1980, Theunis, et al, 2013,Schwendener, et al., 2010). The blood brain barrier is an 
effective barrier against most drugs, except those that are lipophilic, so the use of liposomes 
to bypass it has merit. The addition of proteins to lipid membranes helped to increase 
targetability to tissues, bacteria, or viruses (Lersman, et al.,1980; Bedi, et al., 2011). Proteins 
can interact with cell-surface markers in both the adaptive and innate immune system. By 
using proteins, such as antibodies adhered to the liposomes, it is possible to target liposomes 
away from self-tissues and towards foreign (Schnyder & Huwyler, 2005). For example, 
Scott’s et al., (2007) reported a 92% increase in accumulation of targeted liposomes to 
myocardial infarction compared to liposome alone.  
 
A variety of methods can be used to encapsulate protein into liposomes (Walde & 
Ichikawa, 2001; Lasic & Papahadjooulos, 1996; Meyer, et al., 1994; Tan, et al. 2006; 
Gokhale, et al., 1997; Patel, 1976). These are broadly categorized into active and passive 
loading. Passive loading aims to capture the protein during liposome synthesis. Active 
loading, on the other hand, uses pH gradient to drive the drug of choice into the aqueous 
core following liposome synthesis. This method is highly suitable for encapsulation of small 
molecules (e.g Doxorubicin), but is not feasible for proteins because of their large size and 
isoelectric points. Near the isolectric point, proteins can precipitate out of solution, and at 
low or high pH’s, denaturing can occur. It may be noted that some structure loss is 
reversible, but often the activity of protein is impacted at high or low pH.  
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 Despite significant advancement, the current encapsulation approach fails to prevent 
degradation over time and protein structural damage (Meyer, et al., 1994).  New capacity to 
optimize protein loading into liposome is critically needed. The aim of this thesis project was 
to address the problems associated with extrusion and pH dependent active loading, through 
adoption of an older traditional method of freeze-thaw. Fundamentally, freeze-thaw is the 
use of liquid nitrogen to flash freeze a sample and a warmer thawing temperature, usually 
done in a water bath, to thaw the sample. The contraction and expansion of the lipid bilayer 
allows for the capture of certain drugs, molecules, or proteins in the aqueous core or lipid 
bilayer. Freeze-thaw as a method of protein loading can encapsulate up to 40% of 
Acetylcholinesterase protein (Colletier, et al., 2002), and create small sized liposomes (< 
300nm). This is clinically relevant since large sized nanoparticles are quickly taken up by the 
immune cells, risk cellular damage and may cause thrombotic diseases by absorption from 
the red blood cell and disrupting osmotic pressure (Zhao, et al., 2011).  
 
A critical gap in translation of freeze-thaw methodology is lower loading efficiency 
and temperature induced loss in protein activity. Due to lack of standardized methodology 
for freeze-thaw, the number of freeze-thaw cycles, timing of each of those cycles, the freezing 
temperature, and the water bath temperature are highly variable between various 
laboratories, thereby achieving a range of size, encapsulation efficiency, and cellular 
interaction profiles. One study extruded first then used a freeze-thaw cycle of 3min in a 
liquid nitrogen bath, and a thaw at 50°C for three minutes to achieve a mean diameter of 
14um (Castile & Taylor, 1999). A different study used liquid nitrogen to freeze for an 
unreported amount of time before thawing at 23°C for fifteen minutes (Pick, 1981). Studies 
using different preparations in the lipids, freezing and thawing time and temperatures have 
yielded different results in encapsulation efficacy and liposome size. 
 
In the last decade, freeze-thaw as a method has been witnessing less use in the more 
modern labs partly due to availability of extruders that can create uniformly sized liposomes 
(Benjakul & Bauer, 2000; Xia, et al., 2009). However, modern extruders work at high 
pressure, and thus may not be suitable for protein with delicate conformation.  
 
 The goals of this study were to formulate and characterize protein encapsulated 
liposomes by freeze thaw and extrusion method, and determine the optimal synthesis 
methodology for in vivo protein delivery.  We chose albumin as a surrogate of protein-based 
6 
 
therapeutics since it is cheap and easily available. Albumin is 66KDa with an isoelectric 
point of 4.2. Albumin can detoxify toxins and drugs, and increase the circulation time for 
drugs (Elsadek & Kratz, 2012; Yamasaki, et al., 2013; Jung, et al., 2010; Sleep, et al., 2013). 
While in these experiments, albumin is a place-holder for other potential proteins or 
enzymes, there is a potential avenue to use albumin in conjunction with liposomes to further 
increase circulation time of drugs. Additionally, albumin is not enzymatically active, but can 
be tagged with fluorescent markers (e.g. FITC or Cy5) to provide a measure of encapsulation 
efficiency and cellular trafficking.   
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CHAPTER II 
 
 
OPTIMIZATION OF FREEZE-THAW PROCESS FOR LIPOSOMES SYNTHESIS 
2.1 Abstract 
Background: Freeze-thaw (F/T) can encapsulate proteins into liposomes, however, 
there is no agreed upon single optimized method. The objective of this study was to: 1. 
optimize the number of F/T cycles to achieve a liposome under a specific size limit, and 
2. determine optimal freeze and thaw time.  
 
Method: Lipid films were hydrated with phosphate-buffered saline (PBS), and 
subjected to 10-20 F/T cycles as follows: 1. Five min freeze and five min thaw; 2 min 
freeze, 4 min thaw; and 1 min freeze with a 4 min thaw. 
 
Result: Results indicate that after 15 cycles of freeze-thaw with a 1 min. freeze, 4 min. 
thaw is the most optimal condition for obtaining liposomes in the size-range of 200-
300nm. Shorter cycles with longer F/T yielded larger and non-optimal liposomes 
(300nm + size). 
 
Conclusion: 15 cycles of freeze-thaw with a 1 min. freeze, 4 min. thaw can achieve 
desired size range of under 300nm. 
 
2.2 Introduction  
Freeze-thaw achieves (MacDonald, et al., 1994) fragmentation of multi-lamellar 
liposomes into unilamellar vesicles. The advantage of processing multi-lamellar vesicles 
into unilamillar is size; multi-lamellar liposomes are larger and thus easier for the 
immune system to functionally remove from the body (Hope, et al., 1986).  F/T 
methodology can effectively encapsulate both drugs as well as proteins into liposomes. 
F/T methodology is similar to extrusion that also creates unilamellar vesicles by forcing 
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liposomes through a small diameter filter at high pressure; however, freeze-thaw works 
on the principles of temperature  modules (Costa, et al., 2014; Traikia, et al., 2000; 
Castile, et al., 1999). Freeze-thaw methodology effectively encapsulates not only drugs 
but proteins as well in the liposomes (Meyer, et al.,1994).  
 
The percentage drug encapsulated can be highly variable among various studies 
due to differences in the time of annealing, the number of cycles, and lipids used in the 
procedure (Castile, et al.,1999). For optimal encapsulation, 20 cycles of freeze-thaw has 
been generally adopted as a standard practice (Colletier, et al., 2002). However this 
process can damage the lipid membranes and increase liposome size (Hincha, et al, 
1998). Some studies have reported liposomes under 200nm after five or 10 cycles of 
freeze-thaw (Traikia, et al., 2000; MacDonald, et al., 1994). Attempts to replicate these 
findings by other groups reported contrasting outcomes  with liposome size not 
decreasing to under 200nm with 5-10 cycles of freeze-thaw (Castile, et al., 1999).  
 
Plausibly, the differences in size could be due to variability in freezing and 
annealing duration and lipid compositions (Sriwongsitanont & Ueno, 2011). With a goal 
on achieving liposomes under a certain size (<300nm for systemic use) (Akbarzadeh, et 
al., 2013), here we discuss a novel freeze-thaw protocol. 
 
2.3 Methods 
2.3.1 Liposome thin film preparation 
 All reagents were obtained from VWR unless noted. Lipids were obtained from 
Corden pharma (Switzerland). Liposomes were prepared by hydration using phosphate-
buffered saline (PBS) of a lipid film followed by freeze-thaw. Three phospholipids (2-
dihexadecanoyl-sn-glycero-3-phosphocholine (DPPC), 1,2-distearyl-phosphatidyl 
ethanolamine-methyl-polyethyleneglycol conjugate (DSPE-MPEG),  cholesterol) were 
dissolved in chloroform at a molar ratio of 85.3:9.7:5.0. The chloroform was evaporated 
off at 60⁰C in a rotovap to create a lipid film. This film was dried overnight in a 
desiccator. All assays were performed using six technical replicates generated in parallel 
on the same day. 
 
2.3.2 Optimization of freeze-thaw procedure 
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Freeze-thaw was performed in two stages by optimizing 1) number of cycles of 
freeze thaw, and 2) the duration of each cycle. A cycle was defined as one round of liquid 
nitrogen (-196⁰C) freezing and one round of a 35⁰C water bath thawing. The 35⁰C 
annealing temperature was chosen due to the fragile nature of some thermosensitive 
proteins. 
 
2.3.3. Optimization of the number of cycles and duration of freeze thaw 
The lipid film (as previously stated in 2.3.1) was rehydrated with phosphate 
buffer saline (PBS) using 5mg of lipids/mL of PBS and transferred into 2mL cryo-
protectant vials. Initially, a 5 min. freeze (F), 5 min. thaw (T) was used for size 
determination. Later, we compared additional groups from a 1 min. freeze, 4 min. thaw 
and a 2 min. freeze, four min. thaw. Based on this, a 4 min. thaw was found to be the 
minimum amount of time required to completely thaw a 2mL sample. As controls, half of 
the hydrated samples were also extruded once through a 200nm filter for size 
comparison to liposomes that only underwent F/T. Samples were taken at 0 cycles, 5 
cycles, 10 cycles, 15 cycles, and 20 cycles. Liposomes were sized using dynamic light 
scattering (DLS) equipment (Brookhaven instrument Corporation, 90Plus ZetaPALS 
particle size analyzer). 
 
2.3.4. Statistical analysis 
Treatment groups were compared for differences in mean absorbance using 
ANOVA followed by Tukey's multiple comparisons with GraphPad Prism 6 (GraphPad 
Software Inc.). A p-value less than 0.05 was used as a threshold for statistical 
significance. 
 
2.4. Results 
2.4.1. Optimization of the number of cycles 
 To determine if the number of F/T cycles impacted liposome size, we generated 
liposomes using varied numbers of F/T cycles, and subsequently measured the size of 
the liposomes generated by each methodology. 
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 Results based on 
the six technical replicates 
show that  F/T of 15 cycles 
resulted in a significantly 
decreased size compared 
to 10 or 20 cycles (F = 5 
min, T = 5 min) (p < 
0.05). The size of the 
liposomes dropped from 
2000nm to under 500nm 
after 15 cycles of F/T. 
Surprisingly, 20 cycles of 
freeze-thaw caused an increased liposome size compared to 15 cycles of freeze-thaw 
(Figure 1). …. . Extrusion at any cycle significantly decreased liposome size ~180nm, 
compared to F/T samples. 
 
2.4.2. Optimization of 
the F/T duration 
 To determine the 
effect the F/T duration on 
liposome size, we 
generated liposome batch 
using a varied time on each 
F/T cycle and measured 
the size of the liposomes 
generated by each 
methodology. 
 
 Reduced duration of the F/T achieved smaller liposomes (Figure 2). With a 1 or 2 
min. freeze and 4 min. thaw, liposome size was consistently decreased from ~450nm to 
~200nm than with a 5 min. freeze/5 min. thaw; this trend was particularly prominent 
from 10 to 15 cycles of F/T. In general, average liposome size decreased significantly (p < 
0.05) with a 1 min. freeze, 4 min. thaw at 15 cycles. By increasing the cycles of the F/T, 
liposome size would continue to decrease in diameter. A 1 min. freeze, 4 min. thaw was 
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under 300nM on average after 15 cycles of F/T and was significantly smaller than both 
the 2 min. freeze/4 min. thaw and the 5 min. freeze/5 min. thaw.  
 
2.5. Discussion 
 The advantages and disadvantages of F/T as a viable technique for encapsulating 
proteins in liposomes has been extensively in the past (Costa, et al., 2014; 
Sriwongsitanont and Ueno, 2011; Traikia, et al., 2000; Castile and Taylor, 1999; Hope, et 
al., 1993) (Castile, et al.,1999). These published studies report their own methodology, 
used varying temperatures and yielded different protein encapsulation efficiency and 
liposomal size.  Thus, there is a critical need to standardize freeze-thaw protocol so that 
the scale-up to clinical use can be achieved. 
 
One approach to standardize synthesis methodology could be to use a set thawing 
temperature. To do so, we used a set temperature of 35˚C to thaw all of our samples. Our 
variables, instead, were the duration of each cycle of F/T and the number of cycles of 
employed for liposome synthesis. An important prerequisite in thawing duration is that 
it should liquefy the sample completely. As a first step, we chose a 5 min. freeze-5 min. 
thawing condition that achieved a liposome size of over 300nm after 15 cycles (Figure 1). 
However after adjusting the freezing time to 1min and thawing to 4min, the size achieved 
were under 300nm after 15 cycles of F/T (Figure 2). Additionally, extrusion further 
decreased the size of the liposomes under 200nm in all cases, and there was no 
significant difference across any of the groups likely due to filters that were 200nm and 
resulted in a uniform suspension of liposomes. Thus, extrusion was uniform no matter 
how long or how many cycles of F/T were done. While some studies in the past had 
achieved a liposome size of under 300nm in less than two F/T cycles (Costa, et al., 2014), 
other studies reported contrasting outcomes (Castile and Taylor, 1999). Data from our 
study suggest that increasing the number of cycles to achieve liposomal size below 
300nm is important especially when applying shorter freezing and annealing time. Our 
studies indicated with a 1 min. freeze, 4 min. thaw at 15   cycles, the entire process does 
not take longer than 1 hour. Thus, our methodology is important in protecting 
encapsulated protein from thermal damage at higher annealing temperatures. 
 
A consistent finding in our studies was a decrease in liposomal size with up to 15 
cycles of freeze-thaw. This is in agreement with Traikia et al., 1999 who have shown that 
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liposome composition consisting of dioleoylphosphatidylcholine/dioleoylphoshpatidic 
acid (DOPC/DOPA) can achieve a size under 200nm with greater than 10 cycles of F/T.  
Interestingly, beyond a certain F/T cycle (e.g. 20 cycles), we noted an increase in NP size 
suggestive of liposomal damage. Sriwonsitanot’s & Castille et al., 2011 have reported that 
at higher F/T cycles or low levels of  DSPE-PEG2000, a loss of spherical shape and 
membrane damage can occur. This is interesting, but we did not change our lipid 
composition to explore these effects (see method). Also, the thawing temperatures 
(60⁰C) reported in these studies might not be suitable for protein delivery. We believe 
that our approach of using a 35⁰C thawing might have more widespread use and can 
enhance our ability to encapsulate a wider range of proteins and warrants further 
investigation. 
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CHAPTER III 
 
 
CHARACTERIZATION OF FITC-ALBUMIN LOADED LIPOSOMES 
3.1 Abstract 
Background: F/T methodology currently has a protein encapsulation efficiency that is 
variable based on methodology. The objective of this study was to evaluate and optimize 
encapsulation of protein in liposomes to create a desirable product for in vivo use.  
 
Methods: Liposomes were prepared by 15 cycles of a 1 min. freeze, 4 min. thaw. 
Synthesized liposomes were characterized for encapsulation efficiency, protein release 
and stability in phosphate buffered saline based physiological fluid.  
 
Results: Results suggest that 15 cycles of a 1 min. freeze and 4 min. thaw can achieve 
90% encapsulation efficacy into our liposomes. Synthesized liposome did not differ in 
size compared to the blank liposomes. Liposome size was stable at both 37⁰C and 4⁰C to 
day 28. Release of albumin was minimal till 72 hrs, and at 28 days, liposomes still 
retained 40% of encapsulated protein. 
 
Conclusion: F/T procedure at 15cycles can achieve high encapsulation efficiency and 
liposomes are stable for up to 4weeks at 37⁰C. 
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3.2 Introduction 
 In the last few decades, protein-based therapies are being increasingly applied in 
treatment of cancer, heart disease, and gene therapy (Weidle, et al., 2013; Khan, et al, 
2003; Strayer, et al, 2005). For therapeutic use, a major challenge is the inability of 
current methods to acquire proteins with excellent purity and in high amounts. This has 
been addressed to some extent by discovery of recombinant proteins instead of the 
native form. However, in vivo, proteins last only for couple of hours before being 
removed by the body (Schellenberger, et al, 2009). There is a critical need to develop 
alternative approaches to extend the site-specific concentration of  chosen protein. To do 
so, we hypothesize that encapsulating proteins in liposome may protects its function, and 
enhance its circulation time and targeted delivery. As an initial step, we chose albumin as 
the protein of interest for encapsulation because: 1) Albumin is easily procured in purity 
and amount, and 2) Albumin’s potential as a scavenger molecule for both endogenous 
and exogenous molecules has been well established (Evans, 2002). 
 
 Albumin is synthesized by the liver and serves as a carrier protein in the blood 
and performs numerous functions. Upon systemic injection of drugs, albumin binds with 
them, and this can be leveraged for increasing the circulation time of drugs (Sleep, et al., 
2013; Elsadek & Kratz, 2012), and decrease the likelihood of it being removed by the 
kidneys. It also helps in detoxification by binding to toxins and increasing their ability to 
be excreted in bile or by renal clearance. Purified albumin is readily available, cheap and 
can be easily procured commercially especially for large scale studies. 
 
 Albumin has also been studied to increase the stability of liposomes themselves 
(Jung, et al, 2010; Vuarchey, et al, 2011) and increase their circulation time. However, in 
these cases, the albumin was tethered to the liposome itself and not loaded (Jung, et al., 
2010; Vuarchey, et al, 2011). Albumin can be loaded and used as a marker to determine 
the efficacy of freeze-thaw encapsulation but the reported encapsulation efficacy has 
been variable between studies. The objective of this study was to develop an optimal 
method of protein encapsulation for systemic therapy purposes. As surrogate of protein 
therapeutics, we used bovine serum albumin coupled with a tagged molecule, fluorescein 
isothiocyanate (FITC), a fluorescent marker (excitation: 495nm, emission: 519nm).  
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3.3. Methods 
3.3.1 Synthesis of liposome-FITC-albumin 
 Liposomes were prepared as described in 2.2.1. FITC-albumin was loaded by 
rehydrating the lipid film with 0.17 mg albumin/mL of PBS. Lipid film underwent F/T  
(1min F/4min Thaw: 1/4 F/T) for 15 cycles. Samples (200uL) were drawn at 0, 5, 10, and 
15 cycles. Half of each sample (100uL) at each cycle point was extruded once through a 
200nm filter. All samples were purified using a high centrifugation filter (300kDa cut 
off), and the liposomes were characterized for size via DLS, and encapsulation efficacy 
using spectrophotometry fluorescence (excitation: 420nm, emission: 520nm). For 
optimal reading, dequenching was performed by treating the liposomes with 1% Triton-X 
after purification. Liposome size replicates were technical replicates (n = 6) while 
encapsulation experiments were conducted independently (n = 2). 
 
3.3.2 Release of FITC-Albumin in physiological media  
 FITC-albumin from the liposomes was determined as follows. Liposomes were 
prepared as 3.3.1, and initial encapsulation was determined via fluorescence. The 
samples (extruded and non-extruded) were placed into separate dialysis bags (300kDa 
cut off), and kept at 25⁰C and 37⁰C in 10mL of PBS.  One mL  samples were collected 
daily for seven days and samples were measured for fluorescence (excitation: 420nm, cut 
off: 425nm, emission: 519nm). Each study had 3 technical replicates. 
 
3.3.3 Stability of liposomes in physiological media  
 Long term stability of the liposomes was determined by measuring its size over 
time. To do so, the synthesized lipids were stored in 5mL vials and kept at 25⁰C or at 
37⁰C. Liposome size was estimated using DLS on days 1-7, 14, 21, and 28. 
 
3.3.4 Statistical analysis 
Treatment groups were compared for differences in mean absorbance using 
ANOVA and independent t-tests between groups. A p-value less than 0.05 was our 
threshold for statistical significance. 
 
3.4. Results 
3.4.1 Liposomal Loading with FITC-Albumin 
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 To determine 
the encapsulation 
efficacy (EE) of 
albumin into 
liposomes, we 
generated liposomes 
as previously 
described and loaded 
them with 
0.17mg/mL of 
albumin. After removing free albumin from the sample via centrifugation, we measured 
the excitation and emission of the FITC-albumin to determine the EE. 
 
At 10 cycles of F/T or greater, non-extruded liposome had an EE of~ 90% (Figure 
3). With extrusion, a significant loss in EE was noted at 0, 5, and 10 cycles (p < 0.05) 
with 5 F/T cycles showing the greatest loss. For the extruded group of liposomes, there 
was no significant difference between 0 and 5 F/T cycles, and none between 10 and 15 
F/T cycles. However, there was a significant increase in encapsulation efficacy with 
regards to extrusion from 5 to 10 F/T cycles (Figure 4). 
 
3.4.2 Release of FITC-Albumin in physiological media  
 To determine 
release of the FITC-
albumin from the 
liposomes over the 
course of a week, we 
took a batch of 
liposomes with a pre-
determined EE, and 
separated them into 
dialysis bags at 25°C or 
37°C. Over the course 
of a week, samples of 
the buffer were analyzed for protein release. 
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FITC-albumin was 
noted on day 3 from both 
the extruded liposomes 
and non-extruded 
liposomes (60% and 53% 
respectively). For the 
non-extruded liposomes, 
at day 2 about 10% loss 
was observed that increased to almost ~ 50% on day 3. In contrast, extruded liposomes 
demonstrated no release on day 1 or 2, but had about 60% loss on encapsulated protein 
on day 3 (Figure 5). Following the burst release noted at day 3, non-extruded liposomes 
demonstrated significantly less release compared to the extruded liposomes over the 
subsequent days (47% retained). The extruded liposomes following burst release only 
maintained 40% of their original FITC-albumin. 
 
3.4.3 Stability 
To determine the stability of our liposomes when loaded with albumin, we 
generated liposomes 
and stored at 25°C 
and 37°C. Over the 
first week, we took a 
sample per day before 
changing to once per 
week subsequently. 
 
FITC-albumin 
loading did not 
change liposome size 
(Figure 6). Liposome size over 28 days remained stable at both 25⁰C and 37⁰C (<200nm 
for extruded samples, <300nm for non-extruded FITC-albumin liposomes). Day 1 size 
when compared to day 28 size for all groups (blank liposomes or FITC-loaded) was not 
significantly different (Figure 6). Day 1 size for non-extruded FITC-albumin liposomes at 
25˚C, for example, was 300nm, and after 28 days, the size was still 289nm (Figure 6).  
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     Extrusion of 
liposomes resulted 
in  smaller 
liposomes over 28 
days in that their 
size was 
consistently under 
200nm. At day 1, 
extruded liposomes 
started under 
200nm, and after 
28 days of incubation at either 37˚C or 25˚C, their size remained consistently <200nm. 
 
 In comparison between the two temperatures, there was no significant difference 
between the FITC non-extruded groups, FITC extruded, and the blank extruded groups. 
Temperature did not factor in to size changes between the groups of liposomes. 
Liposomes kept at 37˚C that were extruded did not differ in size after 28 days from 
liposomes that were extruded and kept at 25˚C (Figure 7 & 8). 
 
 To determine whether our liposomes were of a single population or multiple 
populations in size, we 
analyzed the 
polydispersity index. 
Polydispersity is the 
measure of a 
liposome’s population 
size- whether or not a 
group of liposomes are 
uni-sized or have 
multiple populations of 
multiple sizes. For polydispersity index, there was no significant difference in that 
population size and was consistent across the entire month period within a group of 
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liposomes at one temperature or when compared between liposomes kept at 25°C and 
37°C (i.e. extruded at 25⁰C and extruded at 37⁰C) (p = .15)(Table 1 & 2).  
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3.5 Discussion 
 Effects of serum/plasma components on the integrity of liposomes are not readily 
generalized, as they vary among individual liposomal formulations and preparation 
methodology, and thus must be determined empirically. Therefore, to yield a consistent 
product of desired size and stability we determined the stability of albumin-liposome in 
PBS over one month. Our data suggest that the liposome size (F/T average = 300nm; 
blank average = 400nm) and the polydispersity index (markers of structural stability) 
did not change at either 25⁰C or 37⁰C for a period of one month (extruded or non-
extruded).  This was in contrast to encapsulation efficiency that showed only 40-50% of 
the protein retention in the liposomes after 72hrs; although the non-extruded liposomes 
(15 cycles F/T) had less protein release (~7%) over the week period. The discrepancy in 
size and albumin release needs further investigation, but we speculate that if the 
liposome is stored frozen within the first 72hrs post-freeze-thaw, then the release can be 
minimized/controlled.  
 
Our encapsulation efficiencies were comparable to those observed in previous 
studies (Zhao & Lu, 2009; Colletier, et al., 2002; Xu, et al., 2012),  In our study, 15 cycles 
of F/T yielded the best encapsulation efficacy (~90%) of the protein, and least loss upon 
extrusion. This method of F/T is relatively superior to a previous study (Dhoot, 2003), 
wherein FITC-albumin encapsulated via sonication achieved an encapsulation efficiency 
of 50-55%. During this process, similar to sonication, albumin is captured and retained; 
however unlike sonication, F/T includes the energy change of multi-lamellar to 
unilamellar liposomes and size changes associated with heating and freezing that likely 
was more effective in encapsulation under our conditions. Protein release pattern was 
consistent with Dhoot (2003) et al.  that suggested a significant loss of encapsulated 
protein upon extrusion at 0, 5, or 10 F/T cycles. Further, like previous studies, 
cholesterol incorporation allowed more release of their cargo (Dhoot, et al., 2003). 
However, unlike previous studies that notice burst release of FITC-albumin after 24hrs 
(Hua, 2014) from the liposomes prepared with sonication, our data suggest a more 
robust encapsulation of proteins by F/T method (Figure 9), and suggest retention up to 
50% of encapsulated protein for 30 days. The differences in results could be due to 
higher amounts of cholesterol (7:3 ratio of phosphatidylcholine and cholesterol) relative 
to our formulation that had a molar ratio of 85.3:9.7:5.0 ratio (cholesterol being the 
minimum amount added).  We also speculate that the albumin may not have been 
31 
 
entirely encapsulated but was retained on the surface of the liposome in liposomes with 
higher cholesterol content. Albumin, due to its size and anionic nature, is cell membrane 
impermeable, and  can associate with positive groups on the liposomes surface. Presence 
of  the PEG theoretically can prevent such interactions and may improve liposome 
retention for  a relatively longer period.    
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CHAPTER IV 
 
 
LIPOSOMAL INTERACTIONS WITH CELLS IN VITRO, AND FREEZE-THAW 
MEDIATED PROTEIN STRUCTURAL CHANGES  
4.1. Abstract 
Background: Targeted cell-specific therapy of albumin-liposome requires an 
understanding of the structure altering properties of the freeze-thaw on proteins, and 
uptake and trafficking rates by various cell types. The objectives of this study were the 
following: 1) Determine the interaction of liposomes with red blood cells (RBCs), 
macrophages and lung epithelial cells; 2) Quantify the rate and mechanism of uptake, 
and 3) Determine protein structure and activity upon freeze thaw.  
 
Methods: Liposomes were incubated with red blood cells (RBCs), macrophage and lung 
epithelial cells at 37⁰C. Epifluorescence microscopy was performed at 1hr following co-
incubation of liposomes with cell. Flow cytometry was conducted to quantify cellular 
uptake over time (15min, 30min, 1hr, and 2hr).  Protein structure in liposomes upon F/T 
was analyzed using circular dichroism (CD).  
 
Results: Liposomes were taken up by an endosomal route. The rate of uptake varies 
significantly between the extruded, non-extruded liposomes, and free albumin. At 2 
hours, free albumin demonstrated relatively greater phagocytosis than liposomal 
albumin. Additionally, the rate of uptake of albumin liposomes was highest in 
macrophages with intermediate to minimal phagocytosis in lung cancer and RBC cells. 
Protein structure was negatively impacted by freeze-thaw and the damages were more 
profound compared to encapsulated form. 
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Conclusions:. Liposomal encapsulation of protein reduces its cellular uptake. F/T can 
impact protein structure if in free from. Protein encapsulation in the liposome can 
preserve some of the secondary structure and prevent protein damage. 
 
 
4.2. Introduction 
 Conventional drug therapy has limited specificity and can cause toxic side effects. 
To address this problem, currently drugs are encapsulated in nanoparticles as a means to 
achieve site specific delivery. A variety of drug delivery system are currently under 
investigation. This includes  gold nanoparticles (Ghost, et al., 2008, Zensi, et al, 2009), 
polymers (Davis, 2009), and lipid based nanoparticles (Xu, et al, 2009). Of these,  
liposomes have a bilayer structure with an aqueous core, and can encapsulate both 
hydrophobic and hydrophilic drugs. 
 
Liposomes can enter a cell by a variety of mechanisms including: endocytosis; 
absorption; and lipid transfer (Pagano, & Weinstein, 1978). However, the rate of its 
uptake is highly variable between cells (macrophages, cancer cells etc.).  In general,  no 
uptake is seen in the red blood cells due to absence of endosomes in RBCs, however, 
liposomes may cause RBC hemolysis, and thus can serve as a marker for cytotoxicity 
(Iren, et al., 2003, Stork, et al., 2013). Hemolysis below 10% is considered safe in the 
human body (Mocan, 2013), and thus, optimal dosing is critical to avoid cytotoxic events 
upon nanoparticle therapy.  
 
One approach to prevent hemolytic interaction and dissuade preferential uptake 
by the phagocytic cells is by modulation of the physicochemical properties of the 
liposomes (e.g. size). For example, larger (>80nm) liposomes tend to be taken up by the 
immune cells (e.g. macrophages)(Badiee, et al., 2012); however, macrophages cannot 
identify liposomes or nanoparticles under 80nm. Thus, an elegant approach to avoid 
phagosomal uptake can be by creation of small-sized liposomes using extrusion method. 
In some cases especially for protein delivery, extrusion is not the preferred methodology 
since it can cause conformational changes in protein structure. One approach to address 
this issue has been loading of proteins using F/T methodology. However, F/T creates 
larger and less uniformly shaped liposomes causing it to interact with cells in a different 
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manner (Traikia, et al., 2000). To verify these anomalies, in this study we quantified the 
uptake mechanisms of liposomes by fluorescent microscopy, flow cytometry, and 
hemolysis assay.  
 
As noted earlier, liposome synthesis methods (F/T vs extrusion) can also impact 
protein structure that may influence the activity and encapsulation. There is some 
evidence of  proteins denaturing even with F/T (Chang, et al., 1995), and  the loss in 
activity was proportional to protein concentration in the sample (Jian & Nail, 1998). In 
contrast, Chaize et al. observed least amount of damage compared to other 
methodologies of encapsulation (Chaize, et al.,2003). Thus, it is important that F/T 
needs optimization prior to clinical use. 
 
To evaluate liposomal protection of protein, in this study we used circular 
dichroism (CD). CD was discovered in early 19th century by Jean-Baptiste Biot. The 
concept is based on the light that is absorbed differently by the alpha helixes of a protein 
compared to the β-sheets of a protein. This allows to help determine changes in a 
protein’s secondary structure in liposomes and other proteins (Jullien, et al., 1988; 
Hirak & Lentz, 2012). In our CD studies, we determined secondary structure of both free 
and liposome encapsulated liposomes to determine nanoprotection. Although damage to 
secondary structure cannot predict potential damage in tertiary form, yet it may still 
serve as a good basis to understand the impact of synthesis methodologies.   
 
4.3. Methods 
4.3.1 Cell Culture 
A549 alveoli cancer cell line and the RAW 264.7, macrophage cell lines were 
kindly provided by Dr. Lin Liu (Oklahoma State University). A549 cells were grown in 
RPMI media. RAW 264.7 cells were grown in DMEM media (Life Technologies).  Cells 
were incubated at 37°C at 5% CO2. Both media contained 10% fetal bovine serum (Sigma-
Aldrich).  Both media were supplemented with 1% Penstrep.  Red blood cells were 
obtained from a bovine donor (OSU IAUCC approval), and were stored at 25°C until use 
(within 24hrs). 
 
4.3.2: Uptake mechanism determination by fluorescent imaging: 
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To determine liposomal interaction with cells, we used FITC-albumin 
encapsulated liposomes.  
 
Liposomes were prepared as described in section 3.3.1. A549  cells were grown 
overnight (90% confluence) in 6-well plates in a 5% CO2 at 37⁰C. Cells were incubated for 
one hour at 37⁰C with: free FITC-albumin (0.17mg/mL), FITC-albumin loaded 
liposomes that underwent just 15 cycles of freeze thaw (non-extruded group), FITC-
albumin loaded liposomes that were formed by both 15 cycles of freeze thaw and one 
round of extrusion (extrusion group), and a non-liposomal control with just PBS. Prior to 
imaging, cells were rinsed with PBS three times and the nucleus was stained with 4,6-
diamidino-2-phenylindole (DAPI). Additionally, the cell membrane and the endosomes 
were dual-labeled with a green membrane stain: pkh 67 (Sigma-Aldrich, catalog 
PKH67GL-1KT) according to the manufacturer’s protocol to determine endosomal 
uptake.  
 
Red blood cells were not stained due to their natural fluorescence. Cells were 
imaged using an IX-81 confocal fluorescent microscope using a DAPI (exposure = 10ms, 
excitation: 358nm, emission: 461nm), TRITC (exposure: 100ms, excitation: 545nm, 
emission: 600nm), and FITC (exposure: 100ms, excitation: 493nm, emission: 513nm) 
filter.  
 
4.3.3: Quantification of liposome uptake by flow cytometry 
Flow cytometry was used to quantify the rate of uptake of the liposomes into the 
RAW 264.7 macrophage cells. Cells were incubated with extruded and non- extrusion 
FITC-albumin liposomes (15 F/T cycles at 1 min F, 4 min T) for 15 min., 30 min., 1 hour, 
and 2 hours. Prior to imaging, the cells were washed twice with phosphate-buffered 
saline to remove any nonphagocytosed nanostructures. The fluorescence intensity of 
each sample was analyzed by fluorescence-activated cell sorter flow cytometry (BDFACS 
Aria). Assays were performed at room temperature, with time run averaging under a 
min. per sample. 
 
4.3.4 Hemolysis assay to determine cellular toxicity  
To determine liposome toxicity, RBCs were centrifuged at 1500rpm for 15 min., 
and then washed three times with PBS. Then, FITC-albumin liposomes (extruded and 
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non-extruded) at 5mg FITC-albumin/mL in PBS were incubated with the red blood cells 
along with appropriate controls ( free albumin and PBS) for four hours at 37⁰C with 
gentle shaking. After incubation, the cells were centrifuged at 1300rpm for 15 min. The 
supernatant was collected and the absorbance was measured at 394nm. PBS and water 
was used as positive and negative control markers of hemolysis (Chen, et al., 2008).  
 
4.3.5 Assessment of protein damage by circular dichroism 
 Liposomes for CD were prepared and loaded with FITC-albumin as described in 
Section 2.3.1. and Section 3.2.3. As additional control, free bovine serum albumin was 
used and underwent the same 
procedure. Samples were 
analyzed at 0, 5, 10, and 15 cycles 
by CD via spectra-analysis which 
analyzed secondary structure of 
albumin using light rotation. 
After initial results were 
obtained, liposomes were lysed 
with 10% acetonitrile to observe 
the encapsulated protein in a 
free state.  
 
4.3.6 Statistical methods 
 For pairwise comparison,  
a 2- tailed independent t-test was 
conducted (p < 0.05). To 
compare across multiple 
treatment groups, an ANOVA 
followed by pair-wise comparison 
was used (p < 0.05). 
 
4.4. Results 
4.4.1 Uptake mechanism determination by fluorescent imaging 
 FITC-albumin liposomes were phagocytosed successfully upon incubation with 
the macrophage and A549cells (Figures 9A & B) by endosomal mechanism.  Liposomes 
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were localized in the 
endosomes/lysosomes as 
indicated by distinct 
yellow-to-orange spots 
formed by co-localization 
of green nanoparticles and 
red membrane (Figure 
10A & B). No nuclear 
infiltration in either cell 
line was observed, and 
there was no uptake in red 
blood cells (data not 
shown due to absence of 
fluorescence).  
 
4.4.2: Rate of 
liposome uptake by 
flow cytometry:  
 The median 
fluorescence intensity of 
FITC-liposome in RAW 
264.7 macrophages 
showed a significant 
increase uptake over 
time (p < 0.003) 
(Figure 11). Figures 12 
& 13 are representative 
images of flow 
cytometry data 
acquired showing the 
threshold for positive 
cells (i.e. cells that have 
actively taken up the 
FITC-albumin 
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liposome). The rate of uptake varied slightly between extruded (~30%) and non-
extruded liposomes (~26%) at 2 hours.  
 
4.4.3 Hemolysis assay to determine 
cellular toxicity  
 Both FITC-albumin liposomes and 
the free FITC-albumin demonstrated no 
hemolysis (Figure 14), and the percent 
hemolysis was less than 1%, between 
groups (data not shown). 
 
4.4.4 Protein Structure 
 To determine the potential effects 
F/T had on albumin, we generated a batch of liposomes under conditions described in 
3.2.3. and measured the protein change via CD. 
 
  Significant change in secondary structure of free albumin at 5 (~18%), 10 and 15 
(26.5%) cycles of freeze-thaw (p < 0.05) (Figure 15), compared to the free control 
albumin was noted. An increased damage of protein was noted upon extrusion (~63% at 
15 cycles)  when compared to the protein that only underwent freeze-thaw (p < 0.05) 
(Figure 16). In contrast to free albumin, albumin-encapsulated liposomes demonstrated 
minimal damage at 5 cycles, however at 15 cycles, the secondary structure ( 25.8%) 
change was similar to free albumin (Figure 17). When extruded after 15 cycles of F/T, 
there was 38.1% change in structure, thereby suggesting that encapsulation afforded 
about 50% protection in protein structure (Figure 17). When acetonitrile was incubated 
with the liposomes and free albumin, we observed denaturing of the free albumin to a 
complete loss of secondary structure; however, when encapsulated with no extrusion, the 
albumin was able to retain ~45% of its original structure (Figure 18). Figures 19-22 are 
breakdowns of Figure 18. 
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4.5 Discussion 
 The overall goal of our study was to understand the liposomal cellular interaction 
and structural changes in the encapsulated protein upon F/T. For liposomal cellular 
trafficking studies, A549 lung epithelial cells and RAW 264.7 macrophages were used. 
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Fluorescence microscopy was employed to understand the route of uptake in cells and 
the rate of uptake was quantified by flow cytometry. Data suggest that FITC-albumin 
liposomal uptake is mainly by endosomal route which is consistent with previous reports 
(Lee & Low, 1994; Pagano, & Weinstein, 1978; Chan, et al., 2012. Further, in immune 
cells such as RAW 264.7,  FITC-albumin accumulation was also noted  in the cytoplasm, 
likely by micropinocytosis (Makino, et al., 2003). Quantitatively, the rate of uptake of 
FITC-ALB -liposomal in macrophage was greater than the A-549 (~25%, Figure 20). This 
is expected since the immune cells are natural phagocytic cells and are adept at removing 
foreign material, and have a propensity to take-up foreign materials.  Previous studies 
have shown that liposomal coating of protein by PEGylation minimizes its interaction 
with immune cells, and enhances the circulation time of drug molecules. We also noted 
similar findings since the rate of uptake of free albumin was greater than the liposome 
encapsulated protein at 2h of incubation. Metabolically active cells such as macrophages 
can ingest foreign molecules by phagocytosis or micropinocytosis. In contrast to 
macrophages, RBCs cannot perform endosomal uptake since their primary function is in 
oxygen transport. To verify this hypothesis, we incubated the RBCs with the liposomes. 
Results indicated no uptake as expected.  
 
 To determine the effect of F/T on encapsulated albumin (mostly an alpha-helical 
protein (67%)), we measured the structural change via CD. Data suggest that  structural 
changes initiate at 5 F/T cycles. These changes were more pronounced for the free 
albumin that frequently transitioned from an alpha helical nature to beta sheet. 
Similarly, the encapsulated albumin also showed random coil generation, however, the 
difference in elipticity from the different cycles was more limited when the FITC-
albumin was encapsulated compared to the free FITC-albumin in that the fold difference 
when encapsulated was limited (no change up to 5 cycles, <less than 1-fold change from 
5- 15 cycles of freeze thaw). In contrast, the fold change in free albumin structure was 
greater than 1x. An unexpected finding in our study was the preservation of protein 
structure in liposomes in the presence of organic solvents (e.g. acetonitrile, Figure 27). 
This protective effect was also seen in the case with the free protein that underwent 
extrusion, and requires more evidence to confirm these findings. Regardless, an increase 
in F/T cycles is associated with a proportional increase in damage, and this agrees with 
previous studies (Cao, et al., 2003; Benjakul, et al., 2000).  We also observed protein 
damage via extruding of the free BSA through a filter at high pressure one time may have 
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caused a significant change in protein structure. Interestingly, encapsulating the free 
albumin into liposomes can prevent this effect by decreasing the damage by 1.6x fold. In 
summary, it is clear that both F/T and extrusion cannot prevent protein damage (Pikal-
Cleland, et al., 2000). Methods to limit damage should include an optimal buffer type 
with low salt crystal, an optimize protocols that can achieve fast freezing to partially limit 
the damage (Cao, et al., 2003, Pikal-Cleland, et al., 2000). For dosing, such damage 
should be accounted for prior to administering in a patient.  
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CHAPTER V 
 
 
SUMMARY 
F/T has been shown to be an efficient method of protein encapsulation. (Costa, et 
al., 2014). Despite extensive use, widespread variation exists in the encapsulation 
efficiency (EE) and size of liposomes.  Our studies indicate that the number of F/T cycles 
is a crucial factor since F/T beyond the optimal numbers (~ 15 cycles) may damage lipid 
membrane, thereby preventing the liposomes from holding a spherical shape. The ability 
to maintain spherical bilayer shape is also dependent on adequate freezing and  thawing 
of the sample. In general, a 1 - 2 min. thaw is insufficient to completely liquefy a frozen 
liposome sample (Castile & Taylor, 1999). Our data suggest that a 4 min. thaw at 35°C 
can optimally thaw a sample  in a time efficient manner, and achieve size controlled 
liposome similar to that of extrusion process. Loading of small molecules (e.g. anticancer 
drugs) in liposomes is relatively different than large molecules (e.g proteins such as 
albumin), and it is conceivable that this may impact liposome size.  Our data suggest   
that F/Ting the albumin-liposome samples for 5 cycles or greater achieves a conversion 
from multilamellar to unilamellar liposome form and achieves a dramatic decrease in 
size from 16000µm to less than 1µm. Further, at 10- 15 cycles of F/T, an average size of 
less than 300nm is achieved. Thus, the loading of albumin seems to have no detrimental 
effect on the liposome size.  
 
Compared to previous study that reported 40-50% EE after 20 cycles F/T (Costa, 
et al., 2004), we observed an EE of 90% after 15 cycles. It appears that a 4 min. thawing 
at 35⁰C is optimal for wrapping lipids around the protein and for achieving a higher 
encapsulation efficacy. We also believe that this method of thawing is a significant 
improvement over extrusion methodology that also achieve smaller size but is often has 
lower EE (Costa, et al., 200).  
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An ideal goal of liposome loading of proteins is the minimal release of the 
encapsulated content in physiological fluids. Our data suggests that at 72 hours, ~40-
50% of the encapsulated protein is released in physiological media.  Interestingly, this 
loss of encapsulated protein did not coincide with any changes in liposome size or 
polydispersity index. Although the reasons are not known, we speculate that there could 
be partial damage to lipids during F/T and that exacerbates in physiological fluid, 
resulting in a greater protein loss over time.  Alternatively, the protein may not be 
encapsulated but remain attached to the outside membrane, and this could break off into 
free form in PBS; a future study using a protease should be conducted to eliminate this 
potential hypothesis.  
 
Cell specific nanoparticle therapy requires precise targeting. Since PEGylation 
minimizes liposome interaction with immune cells, this may consequently increase 
uptake by other cell types. Our studies show that the uptake of liposome-albumin by the 
macrophages is relatively lower compared to free albumin, thereby validating the 
prevailing hypothesis. We also noted that both F/T and extruded liposomes are taken up 
by the macrophages by endosomal route, thereby indicating that uptake rates are 
independent of synthesis methodology. In some cases , cytoplasmic localization of NPs 
was noted in the macrophages at 2h of incubation. This is likely due to high rate of 
pinocytosis mediated uptake by the macrophage cells.  Interestingly, the RBCs  showed 
no interactions or uptake as reported elsewhere (Vranic, et al., 2013). It is conceivable 
that the lipid bilayer of the RBC can physically interact with liposome, but such contacts 
may be very weak in the absence of endosomal mechanism, presence of PEG on liposome 
surface, and at shorter incubation time (<2-3 hr). There are some report in literation that 
points suggest induction of hemolysis by PEG molecules (Mocan, 2013; Chen, et al., 
2008), but this was not observed in our studies. Future experiment should include 
longer incubation protocols to throw more light on this observation. Similarly, nuclear 
infiltration in both macrophage and lung epithelial cancer cell line were not observed 
since the nuclear pores are ~40nm, and the liposomes with a > 150nm and above 
(Stewart, 1992) may not escape the endosomes efficiently. In summary, F/T achieves 
optimal size and EE, without significant hemolysis.  
 
Finally, circular dichroism data suggest protein structural changes with freeze-
thaw. In the native protein at 5 cycles of freeze-thaw, the structure was 82% similar, but 
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at 10 cycles, it dropped to 61%. Encapsulating the protein in liposome can help stabilize 
the protein, and the resulting damage is not as pronounced as the free form of albumin 
protein. Thus, by creating a method that can optimally load protein in liposomes, this 
study can ease translation of many protein therapeutics, and thus has high translational 
potential. 
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